TNFSF13 and plasma cell myeloma: Besides, existing researches have clarified that the overexpression of TNFSF13 associates with more severe classification and worse prognosis in diverse cancers, including breast cancer (31), multiple myeloma (32), non-small-cell lung cancer (65), and pancreatic cancer (66).